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Abstract 
Cryptococcus neoformans is an emerging pathogen that kills hundreds of thousands every 
year, especially in underdeveloped areas with little access to modern medical care. New 
treatments for the disease are needed to shorten treatment and decrease the side effects 
and costs associated with the drugs currently in use. Many C. neoformans genes have 
been identified that are necessary for full virulence in the host. Cir1, a regulatory protein 
associated with iron regulation, and Zip1, a surface zinc transporter, are both necessary 
for full virulence in the host. Anti-fungals targeted at these proteins or the proteins 
produced by other genes discussed in this paper could help treat this AIDS-defining 
illness more effectively.  
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Non-Capsular Virulence Factors of Cryptococcus neoformans 
Introduction 
Cryptococcus neoformans is a fungal pathogen that mainly infects 
immunocompromised individuals and is an AIDS defining illness. The death rates for 
patients who complete the full course of treatment are extremely low, however, if the full 
course of treatment cannot be carried out the prognosis is poor. A very high percentage of  
C. neoformans infections in immunocompromised individuals in sub-Saharan Africa 
result in death, even when treatment with fluconazole is performed (Mwaba et al., 2001; 
Oumar, Dao, Ba, Poudiougou, & Diallo, 2008). This disease is the fourth most deadly in 
the sub-Saharan region, where it kills more than 500,000 people per year (Park et al., 
2009). Alternative methods for the reduction of both the virulence of the pathogen and 
the length of the course of treatment are needed to improve the survival rate of those 
without easy access to medical care. 
Cryptococcosis has spread concurrently with HIV in Africa and India, and has 
become a much higher priority illness to treat in recent years. A C. neoformans infection 
requires a much longer treatment course than that required by other prevalent African 
diseases, such as malaria or other parasitic infections. Current treatment indicates an 8-
week course of amphotericin B and flucytosine, followed by daily fluconazole for a year. 
This treatment plan is very effective and has a high success rate. However, for those 
without easy access to medical services, a yearlong course of fluconazole may well be 
out of reach, contributing to the high rate of mortalities to the disease observed in sub-
Saharan Africa.  The need for regularly administered antifungals as well as the toxicity of 
those medicines make completing a full course of treatment very difficult. Amphotericin 
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B in particular is extremely toxic and can cause blurred vision and weakness. Flucytosine 
also has relatively severe side effects, ranging from diarrhea and jaundice to headaches 
and hallucinations.  An ongoing shortage of flucytosine also contributes to the difficulties 
associated with obtaining appropriate treatment in developing countries.  
The side effects from these drugs are often severe, and further increase the 
economic barriers preventing patients from being able to complete a full course of 
treatment. The Amphotericin B necessary at the start of treatment alone costs more than 
the average annual income of a resident of sub-saharan Africa. When combined with the 
necessary length of treatment and the need for maintenance anti-fungals for extended 
periods following initial treatment, it is no surprise that mortality rates are elevated in this 
region. New treatment options are badly needed; especially drugs that can treat 
Cryptococcus infection more rapidly or completely eliminate it from the patient, 
preventing the need for maintenance fluconazole.  
C. neoformans is an encapsulated yeast from the phylum Basidiomycota, which 
also includes the mushrooms, rusts, and smuts. Cryptococcus is also the only known 
genera of fungi to have a polysaccharide capsule. It tends to proliferate in the 
cerebrospinal fluid, among other locations, metabolizing the glucose in the CSF as its 
main carbon source. This proliferation can lead to meningitis (swelling of the meninges) 
and encephalitis (inflammation of the brain) due to immune response to the pathogen. 
Both conditions are serious and potentially life threatening. The organism can go dormant 
for extended periods of time, in some cases for ten years or more, only reappearing when 
the host becomes immunocompromised (Garcia-Hermoso, Janbon, & Dromer, 1999). C. 
neoformans also produces melanin, a darkening pigment required for virulence, in much 
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the same manner that the human body does. The production of melanin in the capsule 
helps protect the yeast from attacks by host immune cells. Once in the body, the yeast 
must also be able to grow at 37oC in order to thrive in the host. Many of the mutant forms 
of C. neoformans exhibit temperature sensitivity at 37°C, attenuating their virulence or 
rendering them completely harmless.  
There are several strain variants with different capsule structures with at least one 
substituting xylose for the mannose backbone in the matrix. Two main serotypes of 
Cryptococcus have been characterized in the literature, as well as an interstrain hybrid 
variant (Enache-Angoulvant et al., 2007; Hagen et al., 2015). C. neoformans var. 
neoformans is comprised of serotype D, whereas C. neoformans var. grubii is also known 
as serotype A, while C. gatii contain both serotypes B and C. C. gattii was formerly 
considered a subspecies of C. neoformans (Hagen et al., 2015). The H99 clinical strain of 
C. neoformans is serotype A, while the JEC21 laboratory strain is a serotype D 
strain(Loftus et al., 2005). A serotype AD strain has also been identified and is the most 
widespread of the hybrid serotypes. More serotypes are presumed to exist, but have not 
yet been characterized (Banerjee, Datta, & Casadevall, 2004).  
Pathology 
 Initial infection by C. neoformans is alveolar, as the pathogen in its virulent form 
is airborne. Basidiospores, or sexually-produced reproductive spores, are believed to be 
the initial source of the infection; the vegetative cells are too large to enter the lung 
parenchyma. After entrance to the lung, the now-active cells are absorbed by the alveolar 
macrophages present in the lung tissue. However, phagocytosis by immune cells does not 
kill the yeast; it is able to survive inside of the macrophage due to its unique capsule, 
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where it is shielded from interaction with the immune system. Inside the macrophage, C. 
neoformans can grow and reproduce, creating a phagosome filled with new cells inside of 
the macrophage. After reproducing and combining with other phagosomes, C. 
neoformans is capable of triggering its own release from the macrophage (Alvarez & 
Casadevall, 2006; H. Ma, Croudace, Lammas, & May, 2006).  The phagosome is 
extruded by a process known as vomocytosis, in which the intracellular actin used to hold 
the phagosome in place is degraded (Alvarez & Casadevall, 2006; Nicola, Robertson, 
Albuquerque, Derengowski Lda, & Casadevall, 2011). This process is similar to that 
observed in Mycobacterium tuberculosis, which also use the privileged environment of a 
macrophage to survive intracellularly for extended periods of time (Pieters & Gatfield, 
2002). Non-lytic expulsion of the new yeast cells means that less inflammation occurs, 
reducing the local immune response, and enabling the infection to progress.  
 Many genes in C. neoformans exhibit large increases in expression when engulfed 
by a macrophage. These genes encode proteins necessary for DNA repair, free radical 
elimination, and anti-nitrosative processes, although the yeast is less able to deal with 
nitrogen radicals than reactive oxygen species (Alspaugh & Granger, 1991). The cell wall 
of C. neoformans contains molecules which trigger the M2 activation of macrophages, 
which are less effective against the yeast than M1-activated macrophages (Martinez, 
Helming, & Gordon, 2009). This unequal effectiveness of response is one mechanism by 
which C. neoformans increases its rate of survival in macrophages. M1 macrophage 
activation requires release of inflammatory cytokines, which the intracellular 
reproduction method of C. neoformans reduces. M1 activated macrophages can 
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successfully phagocytose and digest C. neoformans cells due to the reactive nitrogen 
species produced by M1 activation (Alspaugh & Granger, 1991). 
 In case of a successful M1 macrophage activation, granulomas will be formed 
around the Cryptococcus cells in the lung parenchyma and degrading enzymes are 
released (Majka, Kasimos, Izzo, & Izzo, 2002). This reaction is heavily dependent on the 
immunocompetency and genetics of the host, and is similar to the body’s response to 
infection with tuberculosis (Qualls & Murray, 2016). If macrophages are depleted, then 
not enough will be recruited to encapsulate the Cryptococcus infection and it will persist 
(Huffnagle, Yates, & Lipscomb, 1991). Natural killer cells can also bind directly to the C. 
neoformans cells and eliminate them by use of perforin (Levitz, Dupont, & Smail, 1994; 
L. L. Ma et al., 2004). T-helper cells exhibit a fungistatic effect against C. neoformans 
cells (Levitz et al., 1994). The lungs of AIDS patients are lacking in T-cells and 
macrophages, and therefore afford little protection against cryptococcal sepsis (Shibuya 
et al., 2005). 
 After invasion of the lungs and bloodstream, C. neoformans must cross the blood-
brain barrier (BBB). The exact mechanisms used by C. neoformans to cross this barrier 
are still being investigated, but the yeast must pass through the endothelial lining of the 
capillaries, the tight junctions surrounding those capillaries, and the astrocytes that 
protect the neural tissue (Tseng et al., 2015). Monocytes have been shown to be a 
necessary for successful crossing of the BBB by C. neoformans cells, indicating a trojan 
horse effect (Charlier et al., 2009).  Other modes of crossing have also been observed, 
however, including a transcellular mechanism that does not require monocytes (Y. C. 
Chang et al., 2004).  
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 Once the BBB has been crossed, the yeast is free to proliferate in the harsh but 
isolated environment of the cerebrospinal fluid (CSF), as well as brain tissue. This ability 
to thrive in the CSF is not common to all infectious yeasts (Lee et al., 2010). Multiple 
abscesses are formed at the meninges and throughout the brain parenchyma, causing 
fever and headache (Bicanic & Harrison, 2004; Y. C. Chang et al., 2004). Intracranial 
pressure is also frequently increased during cryptococcosis, presumably due to physical 
blockage of the arachnoid villi with yeast cells (Bicanic & Harrison, 2004). The 
mechanism by which C. neoformans is able to survive in the CSF is currently unknown, 
although several mutations that affect survival in the CSF have been identified (Lee et al., 
2010). 
 C. neoformans’ response to resistance by the host immune system is complex. 
Sialic acid is incorporated into the cell wall and released from the cell. This chemical has 
been shown to have a protective effect against phagocytosis by macrophages in the host 
(Rodrigues et al., 1997). Sialic acid also helps to repel other cells by making the cell wall 
of C. neoformans more negative. However, the capsule of C. neoformans is the most 
effective defense against the host immune system. The capsule is a polysaccharide with a 
mannose backbone. Glucuronic acid and xylose are both incorporated into the matrix of 
the capsule as well (Doering, 2009).  
The extracellular polysaccharide matrix has several unique functions. When IgG 
antibodies bind to the C. neoformans cell, they frequently disappear beneath the surface 
of the capsule, preventing them from aiding the macrophages in detection and 
phagocytosis. Free fragments of the GXM capsule (glucuronic acid, xylose, and 
mannose) have been shown to severely inhibit the effectiveness of the host immune 
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response by essentially appearing as false positives all over the body, inhibiting the 
response to actual sites of infection. Coat proteins on the capsule also reduce the host 
response to the infection by reducing the number of co-stimulatory molecules produced 
(Martinez et al., 2009). 
 The carbon cycle in C. neoformans is heavily focused on the use of glucose, much 
like other eukaryotes. The Warburg effect suggests that C. neoformans tends to use 
glycolysis, followed by lactic acid fermentation, to produce energy; this means that 
demand for glucose will be extremely high for C. neoformans to successfully invade and 
proliferate in a host (Vander Heiden, Cantley, & Thompson, 2009). This process is not 
ordinarily energetically favorable, as the electron transport system can generate far more 
ATP per glucose than aerobic glycolysis does. However, proliferating cells also need a 
large variety of organic molecules that are energetically expensive to make from smaller 
carbon molecules. By halting catabolism after production of pyruvate, the cell can 
directly use the carbon from fermentation products at a lower energetic cost than would 
be incurred by using the ATP produced by the citric acid cycle to construct entirely new 
molecules, such as amino acids and NADPH (Vander Heiden et al., 2009). When this 
central carbon utilization pathway is disrupted, severe attenuation of virulence results.  
 Numerous methods are being investigated to reduce the required length of 
treatment to a manageable level for those without easy access to the required drugs for 
extended treatment periods. This research is made more necessary by the difficulty in 
obtaining flucytosine. This shortfall increases the need for alternative modes of treatment 
for Cryptococcosis that can be delivered to areas where conventional medical care may 
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be more difficult to obtain. A better understanding of the carbon usage of C. neoformans 
could lead to new ways to inhibit its growth and aid recovery. 
Regulation of C. neoformans virulence 
Much of the genome of any species of any organism is made up of proteins that 
solely affect the transcription of other genes. C. neoformans has many transcription 
factors which are necessary for virulence, or at least for full virulence. These intracellular 
targets are somewhat more difficult to access than a membrane-bound protein, but their 
effects are widespread and profound. 
GAT201 is a key regulator of virulence which has been shown to impart resistance 
to macrophage function against C. neoformans based on factors other than capsule size. 
This gene regulates over 1000 other genes, or roughly one sixth of the genome of C. 
neoformans. GAT201 has also been shown to be active under conditions in which 
macrophages would be present (Chun, Brown, & Madhani, 2011).  
 Overexpression of GAT201 has been shown to dramatically increase virulence in 
the murine inhalation model (Liu et al., 2008). Overexpression mutants show increased 
melanin production, especially on L-DOPA media, and can induce capsule formation 
under conditions not normally associated with encapsulation (Liu et al., 2008). 
Conversely, gat201∆ strains have shown drastically increased rates of phagocytosis by 
bone macrophages, with approximately a five-fold increase in association between 
macrophages and C. neoformans cells, as compared to strains with gross capsule defects 
(Liu et al., 2008).  
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 The majority of the effect on virulence of GAT201 seems to be caused by its 
regulatory effects on two other genes: GAT204, a transcriptional regulator, and BLP1, 
which encodes a signal peptide (Chun et al., 2011). gat204Δblp1Δ double-knockouts 
show very high levels of macrophage association when co-cultured, approaching a 
significant percentage of that of the gat201∆ strain (Chun et al., 2011). However, 
knockouts of these two regulated genes show no effect on capsule size, indicating the 
source of protection from macrophages is mediated by other factors.  
 Blp1 was identified as a signal peptide which controls functions that have not yet 
been elucidated; although, the presence of a Barwin-like domain indicates that it could 
bind to polysaccharides (Svensson et al., 1992). There is some evidence that either 
GAT204 is a repressor of BLP1, or that BLP1 transcription is increased when GAT204 is 
not present, as in a gat204Δ knockout. blp1Δ strains show only slightly lower resistance 
to phagocytosis compared to wild type C. neoformans. Its effect on virulence appears to 
be largely synergistic with, and dependent on, the presence of a defective GAT204 gene.  
 Gat201 regulates two pathways in C. neoformans: the Gat204/Blp1 pathway and 
an uncharacterized pathway that is not controlled by GAT204 or BLP1 (Chun et al., 
2011). This uncharacterized pathway also protects the cell from phagocytosis by alveolar 
macrophages beyond the effect conferred by the Gat204/Blp1 pathway alone. C. 
neoformans’ survival in the lung is severely impaired by the loss of GAT201, and its 
infectivity is therefore greatly reduced as well. Further research is needed on the exact 
functions of both Blp1 and Gat204 as it is currently unknown what the specific effects of 
these two proteins are; although, the general functions have been inferred by homology 
(Chun et al., 2011).  
VIRULENCE FACTORS OF C. NEOFORMANS 13 
 SRE1 is a highly conserved gene among eukaryotes which regulates response to 
low oxygen conditions (Hughes, Todd, & Espenshade, 2005). It was identified in C. 
neoformans by homology to a similar gene in Schizosaccharomyces pombe. This gene 
encodes a protein known as sterol regulatory element binding protein, which is believed 
to be a membrane-bound transcription factor similar to mammalian SREBP (Bien, 2010). 
The SRE1 gene appears to influence transcription of about 100 genes in C. neoformans 
when under hypoxic (<1% O2) conditions (Yun C. Chang, Bien, Lee, Espenshade, & 
Kwon-Chung, 2007).  
 As the mammalian brain is a relatively low oxygen environment, C. neoformans 
must transition from its normal biosynthetic pathways to ones better suited to low oxygen 
levels (Erecinska & Silver, 2001). SRE1 and SREBP are believed to be essential in 
oxygen sensing in C. neoformans and are key regulators of virulence in both the 
inhalation and tail vein injection murine models (Bien, 2010).  
 Ergosterol is a membrane associated lipid with properties similar to cholesterol 
which is common among fungi and some protists. It is believed to serve a similar 
function to cholesterol in membranes: regulating membrane fluidity. Because mammals 
do not produce this lipid and it is localized at the cell membrane, ergosterol makes an 
excellent target for antifungal drugs. Amphotericin B and the azole drugs target this 
molecule. SRE1 is heavily involved in regulating synthesis of ergosterol at several key 
points in the biosynthetic process (Yun C. Chang et al., 2007). Ergosterol synthesis 
requires large amount of oxygen to synthesize, so its production is downregulated under 
hypoxic or anoxic conditions in many organisms (Hughes et al., 2005). Unlike many 
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other non-capsular virulence regulating genes, SRE1 has no detectable effect on survival 
in alveolar macrophages (Yun C. Chang et al., 2007). 
 Iron and copper metabolism is also regulated by SRE1, with at least 6 different 
iron or copper uptake proteins differentially upregulated under the effects of a functional 
gene (Yun C. Chang et al., 2007).  sre1∆ mutant strains showed greatly reduced growth 
on limited iron medium, with the generational time increasing roughly four-fold (Yun C. 
Chang et al., 2007). Restoration of the gene by complement at least partially restored 
growth on low-iron media.  
The transcription factor MIG1 is involved in regulation of the HAP complex, 
transitioning the transcriptome of S. cerevisiae away from the use of alternative carbon 
sources in the presence of glucose (Nehlin, Carlberg, & Ronne, 1991). A homologue of 
MIG1 in C. neoformans shows similar traits, reducing the transcription of genes 
necessary for galactose, raffinose, and maltose metabolism (Caza, Hu, Price, Perfect, & 
Kronstad, 2016). Loss of MIG1 has a variety of effects, including repression of both 
HAPX and CIG1, a putative heme-binding protein (Caza et al., 2016). The loss of CIG1 
has been linked to a decrease in virulence (Cadieux et al., 2013). This decrease in 
virulence is presumably caused by the loss of iron sourced from hemoglobin. MIG1 is 
also linked with repression of genes necessary for the TCA cycle, including the genes 
responsible for complexes I and III of the electron transport chain (Caza et al., 2016). 
MIG1 is also required for resistance to reactive oxygen species, especially at 37*C (Caza 
et al., 2016).  
 Deletion of MIG1 causes increased susceptibility to fluconazole, to tetracycline, 
and to both anti-fungals combined (Caza et al., 2016). The mig1∆-induced sensitivity to 
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the combination of fluconazole and tetracycline is especially pronounced. Deletion of 
MIG1 has the opposite effect on sensitivity to caffeine and rapamycin. Survival on media 
with these compounds was enhanced in mig1∆ mutants compared to wild type H99 C. 
neoformans (Caza et al., 2016). Testing with high-salt media also showed reduced growth 
for the mig1∆ strain compared to wild type.  
 Despite the sensitivities induced by deletion of MIG1, the mig1∆ mutant strain 
did not show significantly reduced survival in murine macrophages (Caza et al., 2016). 
However, deletion of HAPX in addition to MIG1 significantly reduced the rate of 
survival in macrophages. Mig1∆ mutants were also able to establish an infection in the 
murine inhalation model at a level similar to that of wild type H99 C. neoformans. The 
mutant strain also showed much higher levels of tissue fungal burden in the blood, brain, 
spleen, and liver at time of death compared to wild type. Deletion of HAPX in addition to 
MIG1 significantly reduced infectivity, and reduced fungal burden in the previously 
mentioned tissues to roughly the same level observed in mice infected with wild type 
H99.  
Mig1 seems to regulate sensitivity to a broad range of compounds. Deletion of 
MIG1 causes an increase in sensitivity to fluconazole and tetracycline, but a decrease in 
sensitivity to rapamycin. Rapamycin is not a viable candidate for anti-fungal treatment in 
humans, as it is an immunosuppressant (Abraham & Wiederrecht, 1996). Those suffering 
from a C. neoformans infection are already immunosuppressed, and rapamycin would 
only cause further problems. The increased sensitivity to tetracycline and fluconazole 
makes this gene an appealing target for further research on potential anti-fungals, as these 
drugs are already widely used. Increasing their effectiveness could only be beneficial.  
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Iron metabolism is a key pathway for invading pathogens. Extracellular iron 
levels are normally maintained at a very low level in the human body to reduce its 
availability to pathogens (Jung & Kronstad, 2008). CIR1 is an iron sensing protein in C. 
neoformans which regulates many other genes related to iron metabolism (Jung, Sham, 
White, & Kronstad, 2006). Interestingly, the effects exerted by CIR1 do not appear to be 
dependent on regulation of its expression due to changing iron concentrations (Jung & 
Kronstad, 2011b). Intracellular iron has been found to stabilize the Cir1 regulatory 
protein, which can then bind to its target genes and reduce transcription. CIR1 has also 
been linked to changes in mating and pheromone production, to capsule and melanin 
production, to cell wall proteome, and to other metal ion homeostasis pathways (Jung & 
Kronstad, 2011a, 2011b). Deletion of CIR1 also reduces ergosterol synthesis by reducing 
expression of SRE1 (Jung et al., 2006).  
Deletion of CIR1 reduces virulence drastically, with nearly all major virulence 
markers missing (Jung et al., 2006). The cir1∆ mutant strain is more sensitive to 
antibiotics and was unable to establish an infection in the murine inhalation model. CIR1 
should make an excellent target for potential anti-fungals, as it appears to have homologs 
in many other yeasts (Jung et al., 2006). Its effects on cellular metabolism and 
homeostasis are extremely pronounced, and even small reductions in the efficacy of its 
regulatory function could shorten treatment and improve clearance of a cryptococcal 
infection.  
 SNF1 increases the ability of C. neoformans to grow on non-glucose media, by 
activating numerous glucose repressed genes, and is a key regulator in reversing the 
glucose effect when glucose levels are low. The presence of Snf1 is necessary for growth 
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on galactose, sucrose, and maltose media in JEC21, although it is not essential for growth 
of H99 on those media. This represents a divergence in carbon usage between the H99 
and other yeasts (Celenza & Carlson, 1984, 1989). The function of wild-type SNF1 is to 
reverse the repression of glucose-repressible enzymes and allow the cell to switch to a 
secondary carbon source. This is achieved by increasing production of invertase, which 
splits sucrose into glucose and fructose (Neumann & Lampen, 1967). Removal of this 
gene by deletion made the JEC21 strain largely unable to grow on alternative carbon 
sources. 
 Disruption of the gene SNF1, a key regulator of cryptococcal carbon usage, 
results in defects in carbon usage, melanin production, and capsule formation (Yang et 
al., 2010). Stress response regulation is also a function of this gene. C. neoformans strain 
JEC21 snf1Δ mutants showed reduced growth on glycerol, galactose, and especially 
sucrose media, indicating that the gene is responsible for the same functions in C. 
neoformans as it is in S. cerevisiae. Reconstituted JEC21 showed restoration of normal 
growth on those media. SNF1 has also been linked to regulation of growth at body 
temperature. snf1Δ mutants are far less robust at 37°C compared to wild-type JEC21. 
snf1∆ mutants from this strain also showed reduced ability to grow in media with high 
cation concentration, as well as reduced overall virulence. 
Given the wide variety of stress responses in which SNF1 is a vital component, it 
is no surprise that snf1Δ mutants have reduced virulence. Mice injected with snf1Δ strains 
of JEC21 survived for 72 days, on median, while those infected with the wild type strain 
lasted only 20 (Yang et al., 2010). It is beyond the scope of this paper to infer whether the 
defects in melanin and capsule production were the source of the reduced virulence, but 
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the capsule is the major virulence factor of C. neoformans, so it is difficult to separate the 
effects of metabolic defects from those caused solely by changes to the capsule. 
snf1Δ strains show an unexplained temperature sensitivity at 45°C for two hours 
or 35°C for two days. The presence of a functional SNF1 allele was necessary for 
survival. Complemented and wild type JEC21 were both resistant to the heat treatment. 
H99, again, was largely unaffected by the deletion of SNF1 for this test, further 
emphasizing the divergent functions of SNF1 in the two strains. The role of SNF1 in heat 
shock response is unclear, but it seems to have a regulatory effect on Hsf1, although it is 
only one of several proteins that can participate in Hsf1 activation (Verghese, Abrams, 
Wang, & Morano, 2012).  
 JEC21 also requires a functional SNF1 allele to survive stress induced by high 
concentrations of cations. The snf1∆ strain of JEC21 was abnormally sensitive to high 
concentrations of NaCl and hygromycin B. However, high sorbitol concentrations did not 
elicit the same sensitivity, indicating that high osmolarity is not the source of the 
sensitivity (Yang et al., 2010). snf1Δ H99 did not show increased sensitivity to the tested 
ion concentrations. Nevertheless, the mutant H99 strain did show increased sensitivity to 
amphotericin B, while the mutant JEC21 strain did not.  
As mentioned previously, regulatory proteins make enticing targets for new anti-
fungals due to their broad effects on numerous virulence factors of C. neoformans. Other 
types of targets exist, however, and the digestive and transport enzymes of the cell also 
have the potential to be effective targets for interference. The transport proteins in 
particular are ideal because a potential drug targeted at the protein does not necessarily 
have to make it through the cellular defenses and into the cytoplasm or nucleoplasm. 
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However, metabolic enzymes tend to be much more central to the function of the 
organism and are also worth investigating.  
 Pyruvate Kinase is a key enzyme in glycolysis, the central carbon utilization 
pathway for most non-photosynthetic organisms. Successful acquisition of carbon is a 
vital step in the infection process for pathogens, and C. neoformans is no exception. 
Reduced ability to obtain biochemically useful carbon substrates can reduce ATP 
production and impede production of other key molecules from the pentose phosphate 
pathway. The CSF contains glucose that can be used by an invading pathogen that is able 
to cross the blood brain barrier. Any reduction in the ability of C. neoformans to use this 
glucose would reduce virulence and aid in clearing of the yeast from the host (Price et al., 
2011). Alternative pathways for carbon utilization exist, but an organism that cannot use 
glucose is severely reduced in virulence.  
 Deletion of PYK1 from C. neoformans results in a strain that shows no defects in 
capsule or melanin production, although it does display a temperature sensitivity at 37°C 
(Price et al., 2011). However, this strain is prevented from growing on alternative media, 
such as lactate or glycerol, by carbon catabolite repression. Even though the cell cannot 
use the glucose, the presence of glucose still reduces the ability of the cell to obtain 
carbon from other sources. Deletion of MIG1, the major carbon catabolite repressor 
transcription factor, in the pyk1∆ background enables the strain to grow at near-wild type 
levels on glycerol or lactate media, which do not require a functional pyruvate kinase 
enzyme to enter oxidative phosphorylation. However, the mig1∆ pyk1∆ mutant also 
displayed lower growth rates than those of wild type C. neoformans in permissive media. 
The double-deletion strain also exhibits complete avirulence in the murine inhalation 
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model, although the strain was extremely persistent in the lung with very little clearance 
by macrophages observed (Price et al., 2011).  
 Additionally, production of ATP was drastically reduced in the pyk1∆ mutant, 
which would explain its decreased survival relative to wild type C. neoformans in ex vivo 
CSF(Price et al., 2011). The mig1∆ pyk1∆ double-mutant recovers ATP production in 
CSF, although production is still below that of wild type. Presumably, the limited pool of 
lactate accessible in the CSF results in lower ATP production after glucose repression is 
removed (Price et al., 2011).  
 Drugs targeting the glycolytic pathway have not been used to treat fungal 
infectious diseases yet, but the work by Price and colleagues suggests that an 
appropriately targeted compound could exert a fungistatic effect on C. neoformans even 
after it has crossed the blood-brain barrier and begun to colonize the meninges. 
Presumably, a drug that targets Pyk1 would not also target Mig1 and intracellular ATP 
levels could be drastically reduced, allowing more time for treatment by traditional 
means or for clearance by the immune system.  
 Sterylglucosides are glycolipids which are produced by C. neoformans and are 
present on its surface, but are digested by another enzyme to prevent their accumulation 
(Watanabe et al., 2015). When this enzyme, known as EGCrP2, has been deleted from 
the genome, these sterylglucosides have been shown to accumulate on the exterior of the 
cell and trigger an appropriate immune response by the host. EGCrP2, which is an 
endoglycoceramidase that destroys sterylglucosides on the exterior of the cell, is 
necessary for full virulence of C. neoformans, and is encoded by the SGL1 gene (Rella et 
al., 2015). Deletion of SGL1 does not affect other known virulence factors such as 
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melanin production or capsule size, indicating that a novel protective effect is exerted by 
expression of this gene. 
 Triggering of the TH2 immune response (described below) has been linked with 
decreased effectiveness of immune response and increased overall susceptibility to 
cryptococcosis. Infection with a sgl1∆ strain created by knockout from H99 C. 
neoformans via the murine inhalation model resulted in null virulence (Rella et al., 2015). 
Infection with the sgl1∆t strain also conferred complete immunity against further 
infection by both the sgl1∆ strain and the wild-type H99 strain. This vaccine effect also 
did not appear to be mediated by CD4+ T-cells, as mice depleted of CD4+ cells prior to 
infection also survived infection with the sgl1∆ strain and received the immunity from 
future infections previously observed. This is an exciting discovery, indicating that it is 
very possible to create a vaccine against C. neoformans which could potentially be 
effective even in patients with HIV/AIDS. While introduction of an attenuated strain of a 
pathogen always carries the risk of a reversion mutation, this strain provides a potential 
method to significantly reduce susceptibility to cryptococcosis. 
 A key component of phagocytic attack by macrophages is the use of oxygen 
radicals to damage engulfed cells. Many organisms use the enzyme superoxide dismutase 
to metabolize these peroxides and split them into less reactive components. Wild-type C. 
neoformans has a functional superoxide dismutase gene; other enzymes with a similar 
function further increase the ability of the yeast to deal with radicals (Cox et al., 2003).  
 TSA1 is a gene that has been identified by homology to an S. cerevisiae gene as a 
2-cys peroxiredoxin, meaning that is has both an n-terminal and c-terminal cysteine that 
form crosslinks (Missall, Pusateri, & Lodge, 2004). This enzyme confers additional 
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protection against free radicals and significantly enhances C. neoformans’ ability to 
survive phagocytosis. Under conditions of free radical stress, TSA1 production is 
increased nearly four-fold in wild type C. neoformans (H99), indicating that this gene 
used to fulfill its homology-hypothesized function (Missall et al., 2004). Production of 
TSA1 is also upregulated at higher temperatures. This effect has been hypothesized to be 
a result of changes in metabolism at 37°C which increase the amount of internally 
produced oxygen radicals (Missall et al., 2004).  Regardless of its control mechanisms, 
TSA1 has been shown to be a vital part of the process of clearing free radicals. 
 Knockout mutants of TSA1 show drastically reduced survival in media containing 
small amounts of hydrogen peroxide and t-butylhydroperoxide at 30°C (Missall et al., 
2004). Reconstitution of the gene resulted in a return to wild-type phenotype when grown 
under oxidative conditions and virulence approaching that of H99 C. neoformans. This 
data is consistent with the hypothesis that secondary peroxidases are a necessary 
component for survival post-engulfment. Virulence in the murine inhalation model was 
essentially zero for `infection to occur by the normal method. Injection of tsa1Δ C. 
neoformans into the tail resulted in significantly increased virulence, although less than 
that of H99 wild-type in an inhalation-infection model.  
Echinocandins are a more recent class of anti-fungal than those traditionally used 
to treat cryptococcosis: fluconazole and amphotericin B (Denning, 2003). This new class 
of drugs is effective against many forms of fungi, including Aspergillus and Candida 
species. However, these drugs are not effective at clinical doses against Cryptococcus 
infections. The mechanism for this resistance was recently determined to be a lipid 
flippase that is homologous with S. cerevisiae gene CDC50 (Huang et al., 2016).The 
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gene responsible for resistance to the echinocandin anti-fungal drug caspofungin was 
determined by growing a mutagenesis library of KN99 C. neoformans mutants on media 
inoculated with the antibiotic (Huang et al., 2016).  
Several mutants showed decreased growth under the above conditions, but the 
cdc50Δ strain showed the greatest decrease in growth from the effects of caspofungin 
alone. The flippase encoded by CDC50 could prove to be a potential target for new 
drugs, as it is a protein not found in humans. The combination of a drug targeted at this 
protein and an echinocandin antifungal could allow for a much shorter and less toxic 
course of treatment than the current standard of care.   
Zinc is also necessary for many functions within the cell. It is a component of 
alkaline phosphatase, zinc-finger domains of many proteins including Mig1, and other 
enzymes (Lulloff, Hahn, & Sohnle, 2004). The regulatory and uptake systems for zinc in 
S. cerevisiae has been well characterized, but only recently have the plasma membrane 
zinc transporters for C. neoformans been identified (Do, Hu, Caza, Kronstad, & Jung, 
2016). The ZIP family of zinc transporters are the main family of proteins responsible for 
maintaining intracellular zinc levels. The Zip1 transporter has been linked with zinc 
uptake under low-zinc conditions, and Zip2 with intake under normal or zinc-replete 
conditions. Zip1 is an N-glycosylated protein localized to the plasma membrane with 8 
transmembrane domains. Zip2 is also a membrane-localized zinc transporter, but its 
effect on virulence is negligible.  
Deletion of ZIP1 resulted in decreased growth on low-zinc media, while deletion 
of ZIP2 had little effect at any concentration of zinc (Do et al., 2016). Significantly 
higher zinc levels were required for optimal growth for the zip1∆ mutant compared to the 
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zip2∆ mutant, indicating that ZIP1 is responsible for high-affinity zinc transport. Deletion 
of ZIP1 significantly reduced survival in macrophages, as well as virulence in the murine 
inhalation model. Deletion of ZIP2 alone had little effect on either of these two tests, 
further illustrating the dependence of C. neoformans on Zip1 for obtaining zinc. Deletion 
of both ZIP1 and ZIP2 showed effects on virulence and macrophage survival similar to 
those of the zip1∆ strain. The zip1∆ mutant strain also showed no change in melanin or 
capsule formation compared to H99 wild type C. neoformans. The reduction in virulence 
is therefore linked to the decreased ability of the cell to obtain zinc, rather than on other 
mediating factors. Although deletion of ZIP1 does not cause a complete attenuation of 
virulence, the relative ease of access to a membrane protein compared to an intracellular 
target makes Zip1 an appealing target for new drugs. More research needs to be done to 
determine whether deletion of ZIP1 causes increased susceptibility to other antifungals or 
compounds.  
Another active area of C. neoformans research is on the formation of titan cells, 
which are large, polyploid cells (Okagaki & Nielsen, 2012). These titan cells can reach 
100 microns in diameter, much larger than the normal vegetative C. neoformans cells that 
are ≤ 10 microns in diameter. There are also numerous changes in the capsule of the cell 
when a titan cell is formed, including increased cross-linking and decreased permeability. 
Internal transformation also occurs in these cells, including increased amounts of DNA 
and increased formation of vacuoles. As mentioned previously, these cells are polyploid. 
Vegetative C. neoformans cells are haploid, but titan cells can be tetraploid, octoploid, 
and may even be hexadecaploid (i.e. having 16 copies of the genome in a nucleus). 
However, progeny of these titan cells are still haploid. The mechanism by which 
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polyploid cells are produced from haploid cells is believed to be mitotic, but it is 
currently unknown how polyploid titan cells are able to produce haploid progeny. 
Movement of titan cells across membranes is also hampered by the large size of these 
cells, meaning that it is unlikely they will ever leave the lung but may instead serve as a 
source of dissemination.  
Titan cell formation can be triggered by the presence of macrophages or other 
phagocytic cells, such as amoebae. It has been postulated that sensing of phospholipids 
commonly found in phagocytic cell plasma membranes is the trigger for titan cell 
formation. Production of titan cells has been demonstrated to be controlled by multiple 
intracellular pathways, including adenyl cyclase/cAMP control and G-protein coupled 
receptors (Okagaki et al., 2011; Zaragoza et al., 2010). Titan cells are too large to be 
engulfed, and therefore provide a relatively untouchable source of C. neoformans cells in 
the alveolar tissue (Crabtree et al., 2012). Similar to the immune response to other 
parasites, eosinophils are recruited to the lung, potentially indicating an alternative 
activation of the immune system that is less effective at dealing with the non-titan 
vegetative C. neoformans cells (Crabtree et al., 2012). The progeny of titan cells are more 
resistant to oxidative and nitrosative stress than standard C. neoformans cells (Okagaki et 
al., 2010). The method by which this protection from free radicals is conferred by the 
titan cell is currently unknown.  
Several genes have been identified as regulators of titan cell formation. Gpr5 is a 
membrane protein that has been shown to be necessary for titan cell formation, and may 
be a sensor that triggers the transition (Crabtree et al., 2012). It is unknown whether this 
is the sensor that regulates response to coat lipids of macrophages. Ste3a is also believed 
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to be a regulator for the titan cell formation process and is believed to be involved with 
mating type a pheromone response (Okagaki et al., 2010). Both of these regulatory 
proteins are believed to interact with Gpa1, which is another intermediate in the 
regulatory pathway (Choi, Vogl, & Kronstad, 2012). RIM101 is also involved with 
control of titan cells, and is necessary for titan cell formation (O'Meara et al., 2010). 
Deletion of these genes and the resulting decrease in titan cell formation showed 
significantly lowered virulence in the murine inhalation model (Crabtree et al., 2012). 
It is believed that the effects on virulence of the titan cells that are not mediated 
by the changes to the capsule are due to alternative activation of the immune system 
(Crabtree et al., 2012). Similar to how C. neoformans cells cause M2 activation of 
macrophages, activation of the TH2-type immune response is maladaptive. Alterative 
activation of the immune system to deal with the large titan cells tends to reduce response 
to the normally-sized vegetative cells, allowing them to proliferate while eosinophils 
attack the titan cells. Titan cells are extremely resistant to this type of attack, however, 
and can remain in the lung for months (Crabtree et al., 2012). Mice which showed TH2 
type immune activation had much higher rates of dissemination across the blood-brain 
barrier, and also showed reduced recruitment of T and B-cells to the lungs (Garcia-
Barbazan et al., 2016). 
Conclusion 
As would be expected from any complex organism, the list of genes that are 
necessary for full virulence is long and varied. Many of the genes discussed in this paper 
would make good candidates for new drugs, and could substantially increase survival if 
their target genes or proteins could be inhibited. Resistance to antibiotics is always a 
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concern with any long-lasting infection, and the current treatment plans for a C. 
neoformans infection very extended in length and form a fertile breeding ground for 
resistant phenotypes. Fortunately, the fungal genome is relatively resistant to change, and 
complete resistance to the azole drugs is very rare.  
Other methods could also be used to control the spread of C. neoformans. Pigeons 
have been documented as carriers of this disease, and their droppings are believed to be 
the most common way the illness spreads. Population control of wild pigeons could 
therefore be used to limit spreading of the disease. Similarly, in Australia, a type of 
Eucalyptus tree has been shown to be a reservoir of C. gattii in the wild. Finding ways to 
remove or disinfect the trees could be a potential way to reduce to effects of 
cryptococcosis on the population.  
Ultimately, however, as long as AIDS is present in the world, cryptococcal 
infections will occur. The organism is ubiquitous, and extremely hardy and long lasting. 
Programs designed to preserve innate immunity will be more effective in the long run 
than trying to replace the functionality of an immune system with more drugs.  
 Knowledge obtained about the regulatory pathways and cellular defenses of C. 
neoformans against the immune system can also be used to create treatments for C. gattii, 
which does not require that the host lack a functional immune system. This emerging 
disease could cause massive damage if it became resistant to current antifungals, as the 
infection is very difficult to treat, and is usually not detected until the patient experiences 
symptoms related to encephalitis or meningitis.  
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 The Zip1 transporter should be a relatively safe target for new antifungals. The 
CSF is a relatively isolated environment, so any drugs introduced to that reservoir have 
many fewer potential human cells that could be negatively impacted. Care must be taken 
to ensure that neural tissue is not harmed by the introduction of drugs to the CSF, but 
presumably at least one of the proteins discussed above will be completely unique to 
fungi and cause few side effects.  
 For the borderline immunocompetent, finding ways to stimulate M1 activation of 
macrophages rather than the M2 activation encouraged by C. neoformans is probably the 
best option. Stopping the infection in the alveolar tissue of the lung is obviously 
preferable to treating the disease after infection of the CSF.  
 New antifungals are constantly in development, and it remains to be seen how 
effective the latest class of azoles will be against C. neoformans. Isavuconazole, 
developed for treatment of infection by Aspergillus species, targets the production of 
ergosterol. Ergosterol, as mentioned above, has been shown to be necessary for virulence 
in C. neoformans, so this drug has the potential to be useful in treating cryptococcosis. 
However, another azole drug will most likely not be sufficient to significantly reduce the 
burden of treatment for cryptococcosis. Some method of allowing the immune system to 
appropriately respond to the yeast would be ideal, preferably by enabling CD8+ 
lymphocytes, which are not depleted by infection with HIV, to successfully phagocytize 
and destroy the pathogen (Daniel et al., 2001). A drug that could potentially shut down a 
key regulator such as Cir1 could reduce the metabolic capabilities of the cell and make it 
unable to defend against the use of superoxide radicals inside of the macrophage.  
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 Like alternative M2 macrophage activation, triggering of TH2-type immune 
response by C. neoformans titan cells decreases the effectiveness of macrophages and 
increases dissemination across the blood-brain barrier. If proper stimulation of the 
immune system can be achieved, treatment is far more likely to be successful and short. 
As before, the ideal solution is to encourage the immune system to respond appropriately 
rather than to necessitate extended use of antifungals to prevent reinfection.  
 C. neoformans and C. gattii are emerging pathogens that have seen a drastic 
increase in infection as the frequency of AIDS infection has increased. While 
cryptococcosis kills thousands every year, it is currently still treatable by standard 
antifungal drugs with a high survival rate. However, difficulties in obtaining the 
necessary antibiotics, as well as the length of treatment prevent members of isolated or 
low-income areas from being able to complete a full course of treatment. Finding new 
drugs that target the pathways discussed herein should be a priority for the medical 
research community.  
 As with other common microbial infections, the development of strains that are 
resistant to the current drugs of choice is a concern. If more antifungals can be created 
that are effective against C. neoformans, the emergence of highly resistant strains can be 
delayed by allowing rotation of antifungals and for antibiotics of last resort to remain 
effective. Again, like other microbial infections, early detection is the key to preventing 
loss of life from the disease. Regular screening of those with HIV/AIDS for C. 
neoformans infection could help save lives without the introduction of new treatment 
methods. 
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The possibility of a viable vaccine is also being explored, and has the potential to 
revolutionize the treatment of cryptococcosis in a way that reactive treatment can never 
hope to match. Research on vaccination against C. neoformans is still at the very 
beginning stages, but this approach holds considerable promise for those who may 
become infected with C. neoformans in the future. 
 The recent outbreaks of C. gattii are also concerning, and highlight further the 
need for better research on Cryptococcus, as well as more drugs that are effective against 
this hardy pathogen. Several of the mutations described in this paper have the potential, if 
targeted, to allow current and newly created antifungals to be more effective. Whether the 
method of attack is to synergize with existing drugs or to create entirely new courses of 
treatment, the result will be shortened treatment times and increased effectiveness of 
treatment. These two accomplishments would make full and successful treatment a 
possibility for many who are currently unable to afford or find appropriate treatment.  
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